{"title":"高血压成人的多不饱和脂肪酸、APOE基因型与痴呆发病率和死亡率。","authors":"Yubo Zhang, Jindi Li, Shaohui Liu, Quanhong Chen, Xuexiu Wang, Sisi He, Yadong Wei, Yunfeng Zou, Yunan Xu, Lijun Wang, Hao Chen","doi":"10.1016/j.tjpad.2025.100297","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Individuals with hypertension have an elevated risk of dementia. The potential protective effects of dietary polyunsaturated fatty acids (PUFAs) against dementia remain unclear. In this study, we investigate associations between blood PUFA levels and dementia outcomes, while considering the genetic predisposition among hypertensive adults.</p><p><strong>Methods: </strong>We employed data from UK Biobank and a prospective cohort of 123,235 hypertensive participants aged 40-69 years were included for the analysis (2006-2022). Cox proportional hazards models adjusting for covariates were applied to assess the associations of blood levels of docosahexaenoic acid (DHA), N3FA, N6FA, linoleic acid (LA), total PUFA, and the N6FA/N3FA ratio with incident dementia, dementia mortality, and all-cause mortality. The analyses were also stratified by polygenic risk scores (PRS) or APOE genotypes.</p><p><strong>Results: </strong>Higher levels of DHA (HR 0.41, 95 % CI 0.27-0.62), N3FA, LA, N6FA, and total PUFA were associated with significantly reduced dementia incidence (P < 0.001). In contrast, a higher N6FA/N3FA ratio was linked to increased dementia risk. Similar trends were observed for mortality. APOE genotypes, rather than PRS, modified PUFA-dementia associations: individuals with low-to-moderate APOE risk showed greater protective effects of high PUFA levels compared to those with high-risk genotypes.</p><p><strong>Conclusions: </strong>Among hypertensive adults, higher PUFA levels are associated with reduced risks of dementia and mortality. An imbalanced N6FA/N3FA ratio increases risk, while APOE genotypes significantly modify PUFA-related dementia outcomes.</p>","PeriodicalId":22711,"journal":{"name":"The Journal of Prevention of Alzheimer's Disease","volume":" ","pages":"100297"},"PeriodicalIF":7.8000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12413715/pdf/","citationCount":"0","resultStr":"{\"title\":\"Polyunsaturated fatty acids, APOE genotypes, and dementia incidence and mortality among hypertensive adults.\",\"authors\":\"Yubo Zhang, Jindi Li, Shaohui Liu, Quanhong Chen, Xuexiu Wang, Sisi He, Yadong Wei, Yunfeng Zou, Yunan Xu, Lijun Wang, Hao Chen\",\"doi\":\"10.1016/j.tjpad.2025.100297\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Individuals with hypertension have an elevated risk of dementia. The potential protective effects of dietary polyunsaturated fatty acids (PUFAs) against dementia remain unclear. In this study, we investigate associations between blood PUFA levels and dementia outcomes, while considering the genetic predisposition among hypertensive adults.</p><p><strong>Methods: </strong>We employed data from UK Biobank and a prospective cohort of 123,235 hypertensive participants aged 40-69 years were included for the analysis (2006-2022). Cox proportional hazards models adjusting for covariates were applied to assess the associations of blood levels of docosahexaenoic acid (DHA), N3FA, N6FA, linoleic acid (LA), total PUFA, and the N6FA/N3FA ratio with incident dementia, dementia mortality, and all-cause mortality. The analyses were also stratified by polygenic risk scores (PRS) or APOE genotypes.</p><p><strong>Results: </strong>Higher levels of DHA (HR 0.41, 95 % CI 0.27-0.62), N3FA, LA, N6FA, and total PUFA were associated with significantly reduced dementia incidence (P < 0.001). In contrast, a higher N6FA/N3FA ratio was linked to increased dementia risk. Similar trends were observed for mortality. APOE genotypes, rather than PRS, modified PUFA-dementia associations: individuals with low-to-moderate APOE risk showed greater protective effects of high PUFA levels compared to those with high-risk genotypes.</p><p><strong>Conclusions: </strong>Among hypertensive adults, higher PUFA levels are associated with reduced risks of dementia and mortality. An imbalanced N6FA/N3FA ratio increases risk, while APOE genotypes significantly modify PUFA-related dementia outcomes.</p>\",\"PeriodicalId\":22711,\"journal\":{\"name\":\"The Journal of Prevention of Alzheimer's Disease\",\"volume\":\" \",\"pages\":\"100297\"},\"PeriodicalIF\":7.8000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12413715/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of Prevention of Alzheimer's Disease\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.tjpad.2025.100297\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/22 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"BUSINESS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Prevention of Alzheimer's Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.tjpad.2025.100297","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BUSINESS","Score":null,"Total":0}
引用次数: 0
摘要
背景:高血压患者患痴呆的风险较高。膳食多不饱和脂肪酸(PUFAs)对痴呆的潜在保护作用尚不清楚。在这项研究中,我们研究了血液中PUFA水平与痴呆结局之间的关系,同时考虑了高血压成人的遗传易感性。方法:我们采用了来自UK Biobank的数据,并纳入了123,235名年龄在40-69岁之间的高血压患者的前瞻性队列(2006-2022)。采用校正协变量的Cox比例风险模型评估二十二碳六烯酸(DHA)、N3FA、N6FA、亚油酸(LA)、总PUFA和N6FA/N3FA比值与痴呆发生率、痴呆死亡率和全因死亡率的关系。分析还通过多基因风险评分(PRS)或APOE基因型进行分层。结果:较高水平的DHA (HR 0.41, 95% CI 0.27-0.62)、N3FA、LA、N6FA和总PUFA与显著降低痴呆发病率相关(P < 0.001)。相反,较高的N6FA/N3FA比例与痴呆风险增加有关。死亡率也出现了类似的趋势。APOE基因型,而不是PRS,改变了PUFA与痴呆的关系:与高风险基因型相比,低至中度APOE风险的个体显示出更高的PUFA水平的保护作用。结论:在高血压成人中,较高的PUFA水平与降低痴呆和死亡率的风险相关。不平衡的N6FA/N3FA比例会增加风险,而APOE基因型会显著改变pufa相关的痴呆结局。
Polyunsaturated fatty acids, APOE genotypes, and dementia incidence and mortality among hypertensive adults.
Background: Individuals with hypertension have an elevated risk of dementia. The potential protective effects of dietary polyunsaturated fatty acids (PUFAs) against dementia remain unclear. In this study, we investigate associations between blood PUFA levels and dementia outcomes, while considering the genetic predisposition among hypertensive adults.
Methods: We employed data from UK Biobank and a prospective cohort of 123,235 hypertensive participants aged 40-69 years were included for the analysis (2006-2022). Cox proportional hazards models adjusting for covariates were applied to assess the associations of blood levels of docosahexaenoic acid (DHA), N3FA, N6FA, linoleic acid (LA), total PUFA, and the N6FA/N3FA ratio with incident dementia, dementia mortality, and all-cause mortality. The analyses were also stratified by polygenic risk scores (PRS) or APOE genotypes.
Results: Higher levels of DHA (HR 0.41, 95 % CI 0.27-0.62), N3FA, LA, N6FA, and total PUFA were associated with significantly reduced dementia incidence (P < 0.001). In contrast, a higher N6FA/N3FA ratio was linked to increased dementia risk. Similar trends were observed for mortality. APOE genotypes, rather than PRS, modified PUFA-dementia associations: individuals with low-to-moderate APOE risk showed greater protective effects of high PUFA levels compared to those with high-risk genotypes.
Conclusions: Among hypertensive adults, higher PUFA levels are associated with reduced risks of dementia and mortality. An imbalanced N6FA/N3FA ratio increases risk, while APOE genotypes significantly modify PUFA-related dementia outcomes.
期刊介绍:
The JPAD Journal of Prevention of Alzheimer’Disease will publish reviews, original research articles and short reports to improve our knowledge in the field of Alzheimer prevention including: neurosciences, biomarkers, imaging, epidemiology, public health, physical cognitive exercise, nutrition, risk and protective factors, drug development, trials design, and heath economic outcomes.JPAD will publish also the meeting abstracts from Clinical Trial on Alzheimer Disease (CTAD) and will be distributed both in paper and online version worldwide.We hope that JPAD with your contribution will play a role in the development of Alzheimer prevention.